Sun Pharma Announces USFDA Approval of Drug to Treat Prostate Cancer
On July 8, Concert Pharmaceuticals announced that the FDA has granted oral JAK inhibitor CTP-543 as a breakthrough treatment for adults with moderate to severe alopecia areata. Alopecia areata is an autoimmune disease in which the body's immune system attacks hair follicles and causes partial or complete hair loss in the scalp or body. Alopecia areata affects approximately 700,000 people in the United States and is visible throughout men and women. Alopecia areata can cause serious mental health disorders, such as anxiety and depression. The FDA has not yet approved any drugs for the treatment of alopecia areata.
The FDA's decision is mainly based on the excellent efficacy of CTP-543 in the phase II clinical study for patients with moderate to severe alopecia areata. This phase II study used a randomized, double-blind, placebo-controlled, sequential dose design to evaluate the safety and efficacy of CTP-543 in adults with moderate to severe alopecia areata. A total of 149 patients were randomized and given CTP-543 4, 8, 12 mg or placebo twice daily, respectively. The primary endpoint of the study was an improvement in baseline hair loss severity tool (SALT) score at Week 24 of ≥50% from baseline.

The results showed that the CALT-543 8 mg and 12 mg treatment groups had an average SALT score improvement of 78% and 86% from baseline at week 24. The proportion of patients with a SALT score reduction of ≥50% from the baseline in the two groups compared with the placebo control group The statistical difference (58% vs 47% vs 9%, p <0.001) reached the main endpoint of the study.
Dr. Roger Tung, CEO of Concert Pharmaceuticals, pointed out: "I am very pleased to see that FDA has recognized the potential of CTP-543 as a new treatment for alopecia areata. Our goal is to bring this new therapy to patients as soon as possible, and we look forward to working closely with FDA to advance this Drug development."
Registration Is Over: Now What?
2026-10-29
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Red Sun: The company is committed to supply 97% Chlorantraniliprole technical no less than 1000 tons to Sino-Agri this year
-
China丨The first phase of Red Sun's digital transformation project launched
-
Sun Pharma announces licensing agreement with CSIR-IICT
-
UK’s £350 Million Critical Chemicals Fund Enters Formal Review, Offering Up to 50% Support Per Project
-
Colombia Makes Preliminary Ruling in Anti-Dumping Investigation into Chinese DOP Imports
-
Canada Issues Non-Compliance Notice to Dr. Reddy’s on Semaglutide Generic
-
US Pushes G20 to Reassess Trade with China, Raising New Risks for Chemical Exporters
-
Sudden Turmoil in Middle East Shipping Routes: Multiple Carriers Announce Emergency Navigation and Surcharge Policies
-
G20 Pushes Fertilizer Access as Food-Security Risk Rises
-
India Prepares New Seed and Pesticide Laws
Recommend Reading
-
Syngenta Caught in Trade Crossfire
-
MENA Pharmaceutical Regulatory Updates 2026: Key Compliance Changes for Global Pharma Companies
-
EU PIC Amendment Adds Over 30 Chemicals to Control List and Bans 3 POPs Exports
-
FDA Tracks Industry Dye Removal
-
U.S. Finds Methionine Dumping Could Recur, With Japan Margin Up to 76.50%
-
Business Society’s September 14, 2026, Petroleum Coke Trend Analysis: Volatile
-
Business Society’s Gasoline Trend Analysis for September 15, 2026: Volatile Consolidation
-
Business Society’s Trend Analysis for Heavy-Weight Pure Soda Ash on September 15, 2026: Volatile
-
Business Society’s Phenol Trend Analysis for September 15, 2026: Slight Decline
-
Post-holiday China 180CST fuel oil prices slightly increase